Nanoparticle Contract Manufacturing Market (Type of Nanoparticle: Polymer Nanoparticle, Lipid Nanoparticle, Nanocrystal, and Inorganic Nanoparticle)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Nanoparticle Contract Manufacturing market size was estimated at USD 86.8 billion in 2021 and is expected to surpass around USD 176.9 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.10% during the forecast period 2022 to 2030.

Global Nanoparticle Contract Manufacturing Market Introduction

Nanoparticles are used in the formation of nanomedicines. The nanosize of particles, in the range of 1 to 100 nanometers, helps enhance the physiological properties of drugs. There are four types of nanoparticles: nanocrystals, polymeric nanoparticles, lipid nanoparticles, and inorganic nanoparticles. Liposomes and lipid nanoparticles are similar in design. Lipid nanoparticles are used as colloidal carriers for bioactive organic molecules in cancer treatment.

Polymer-based nanoparticles include dendrimers, micelles, drug conjugates, and protein nanoparticles. Inorganic nanoparticles include metal nanoparticles manufactured from gold and silver. Nanoparticle products are also employed in medical imaging and diagnosis. Gold nanoparticles are gaining traction in the healthcare sector due to their ability to detect microbial cells, metabolites, and tumor cells.

Report Scope of the Nanoparticle Contract Manufacturing Market

 Increase in Preference for Contract Manufacturing Augmenting Global Nanoparticle Contract Manufacturing Market Size

Pharmaceutical companies are increasingly preferring contract manufacturing, especially for the production of nanoparticles. Around 60% of nanoparticle products are manufactured through contract manufacturing. Contracting a supplier for medical-grade nanoparticles enables sponsors to leverage new technologies (available with the service provider), access larger capacities, and achieve greater operational flexibility. This helps reduce expenses incurred on resources and time required for production, thus subsequently lowering the cost of final products.

Rise in Prevalence of Cancer and Other Chronic Diseases Driving Global Nanoparticle Contract Manufacturing Market

The burden of chronic diseases across the globe is expected to rise significantly in the next few years. According to the American Cancer Society, the U.S. recorded around 1.9 million new cancer cases and 608,570 cancer deaths in 2021. Nanoparticle products are primarily used for the treatment of cancer. Currently, more than 40% of nanoparticle products are under phase II development. COVID-19 has adversely impacted the overall contract manufacturing market. The pandemic led to a significant decline in the production of nanoparticles.

R&D of New Products Fueling Lipid Nanoparticle Segment

Based on type of nanoparticle, the global nanoparticle contract manufacturing market has been segmented into polymer nanoparticle, lipid nanoparticle, nanocrystal, and inorganic nanoparticle. The lipid nanoparticle segment accounted for significant share of the global market in 2021. Lipid nanoparticles include liposomes, solid-lipid nanoparticles, and exosomes. Currently, more than 20 lipid nanoparticles are available in the market.

Increase in R&D of lipid nanoparticle products is likely to drive the lipid nanoparticle segment during the forecast period. Currently, more than 30 liposome products are in the pipeline; most of these have potential in the treatment of cancer. Lipid nanoparticles provide several advantages such as protection to the DNA from degradative processes and increase in solubility and bioavailability of products.

Growth in Incidence of Chronic Diseases Bolstering Therapeutics Segment

In terms of application, the global nanoparticle contract manufacturing market has been classified into therapeutics, regenerative medicines, diagnostics, vaccines, and others. The therapeutics segment held major share of the market in 2021. Nanoparticle products aid in the treatment of cancer, neurological disorders, and genetic diseases. Thus, increase in incidence of chronic diseases is boosting the therapeutics segment.

Increase in Pharmaceutical Contract Manufacturing Propelling Pharmaceutical Companies Segment

Based on end-user, the global nanoparticle contract manufacturing market has been bifurcated into pharmaceutical companies and biotechnology companies. The pharmaceutical companies segment is anticipated to account for major share of the global nanoparticle contract manufacturing market during the forecast period. Growth of the segment can be ascribed to factors such as rise in preference for contract manufacturing and increase in number of contract manufacturers engaged in development of nanoparticle products.

Regional Outlook of Global Nanoparticle Contract Manufacturing Market

According to a recent analysis of the nanoparticle contract manufacturing market, North America held the largest share of 45% of the global market in 2021. The region is expected to be a highly lucrative market during the forecast period, with a high market attractiveness index. North America's dominance in the global nanoparticle contract manufacturing market can be ascribed to the increase in incidence of chronic diseases in the region. The U.S. dominated the market in North America in 2021, owing to the presence of key market players and increase in investment in R&D of nanomedicines.

Asia Pacific is projected to be the fastest-growing market for nanoparticle contract manufacturing during the forecast period. The market in the region is anticipated to grow at a high CAGR from 2022 to 2030 due to the presence of small- and medium-sized nanoparticle contract manufacturers in the region.

Analysis of Key Players in Global Nanoparticle Contract Manufacturing Market

The global nanoparticle contract manufacturing market is consolidated, with the presence of a small number of leading players. Majority of microparticle contract manufacturers are significantly investing in R&D activities to introduce advanced nanoparticle products in the market. Expansion of product portfolios and mergers & acquisitions are key strategies adopted by players to enhance their nanoparticle contract manufacturing market share.

AstraZeneca, Ascendia Pharmaceuticals, Axolabs, AVANSA Technology & Services, Ardena Holding NV, Cytodiagnostics Inc., American Elements, Encapsula NanoSciences, Fortis Life Sciences, Hongwu International Group Ltd., MyBiotech, Nanochemazone, TechNanoIndia, STA Pharmaceutical Co. Ltd., and Evonik are prominent players operating in the market.

Key Developments in Global Nanoparticle Contract Manufacturing Market

• In September 2022, WuXi STA established a new sterile lipid nanoparticle formulation facility to enhance global CRDMO services for customers
• In July 2022, CordenPharma, a full-service contract manufacturer, invested around US$ 10 Mn in the formulation, development, and production of new lipid nanoparticles
• In October 2020, Fujifilm signed a contract manufacturing agreement with VLP Therapeutics for COVID-19 vaccine formulation. The self-amplifying (replicon) RNA vaccine uses a lipid nanoparticle formulation.

Some of the prominent players in the Nanoparticle Contract Manufacturing Market include:

• AstraZeneca
• Ascendia Pharmaceuticals
• Axolabs
• AVANSA Technology & Services
• Ardena Holding NV
• Cytodiagnostics Inc.
• American Elements
• Encapsula NanoSciences
• Fortis Life Sciences
• Hongwu International Group Ltd.
• MyBiotech
• Nanochemazone
• TechNanoIndia
• STA Pharmaceutical Co. Ltd.
• Evonik

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Nanoparticle Contract Manufacturing market

• Type of Nanoparticle
• Polymer Nanoparticle
• Lipid Nanoparticle
• Nanocrystal
• Inorganic Nanoparticle
• Application
• Therapeutics
• Regenerative Medicines
• Diagnostics
• Vaccines
• Others
• End-user
• Pharmaceutical Companies
• Biotechnology Companies

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Nanoparticle Contract Manufacturing industry analysis from 2022 to 2030 to identify the prevailing Nanoparticle Contract Manufacturing industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Nanoparticle Contract Manufacturing industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Nanoparticle Contract Manufacturing industry trends, key players, market segments, application areas, and market growth strategies.